• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

XTL Biopharmaceuticals Provides Financial and Operational Update For the Full Year Ended December 31, 2014


News provided by

XTL Biopharmaceuticals Ltd.

Apr 28, 2015, 07:45 ET

Share this article

Share this article


HERZLIYA, Israel, April 28, 2015 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the full year ended December 31, 2014.  

Josh Levine, Chief Executive Officer of XTL, commented, "With the recent closing of a $4 million registered direct offering from a US based healthcare-dedicated investor and our existing shareholders, the Company is well positioned to become a leader in drug development as we focus on advancing our core assets for lupus and multiple myeloma. We continue to make great strides in order to initiate a Phase II clinical trial with hCDR1 for lupus. Our discussions with the FDA remain constructive. Furthermore, a leading pharmaceutical company's discontinuation of their Phase III trial for lupus in conjunction with the encouraging results we have from the PRELUDE trial will uncover a myriad of opportunities for our hCDR1 asset. We are also equally excited about rHuEPO for multiple myeloma and remain on track to bring both assets into Phase II clinical trials."

"In tandem with the progression of our assets, we continue to build on the knowledge base from which we can draw to lead the company forward. The six new members appointed to our Board of Directors come with extensive drug development and capital markets experience. The Clinical Advisory Board's expertise on lupus adds immeasurable value to the company as we focus on developing the hCDR1 asset. With the guidance of the preeminent team that we have assembled, I am excited about the prospects that lie ahead of us," continued Mr. Levine.

"We also had Mr. Alex Rabinovitch, our largest shareholder and a prominent Israeli biotech investor, take an increased interest and stake in the company with his participation in our latest round of financing, his investment in InterCure and purchases of Company shares on the market. Our divestiture of InterCure simultaneously streamlines our operations, allows us to focus on our core assets and provides investors with a transparent look at the Company's financials," concluded Mr. Levine.

Financial Overview

Following the Company's divestiture of InterCure, results from the investment in InterCure are presented separately as results from discontinued operations. Consequently, results from continuing operations as presented in the Company's 2014 financial statements, for each of the three years in the period ended December 31, 2014, reflect the drug development activity of XTL only.

XTL reported $2.2 million in cash, cash equivalents and bank deposits as of December 31, 2014. The additional funds added from the fundraise announced on March 31, 2015, will allow the Company to advance its hCDR1 program for the treatment of SLE and initiate a clinical trial on its rHuEPO for multiple myeloma asset.

The Company reported research and development expenses for the year ended December 31, 2014 of $278,000 compared with $82,000 for 2013 reflecting increased investment behind our clinical programs and preparations for clinical trials. General and administrative expenses for the year ended December 31, 2014 were $1.7 million compared with $1.3 million in 2013.

XTL reported an operating loss for the year ended December 31, 2014 of $2.0 million compared with $0.3 million for the same period last year. Operating losses in 2013 included a gain on sale of the Company's investment in Proteologics of $1.1 million.  The Company reported a net loss from continuing operations for the year ended December 31, 2014 of $2.1 million, compared to $1.1 million in the same period last year.

In addition to the results from our drug development activities, our 2014 results include a loss from discontinued operations relating to InterCure of $0.7 million, compared to $2.6 million in the corresponding period.

About XTL Biopharmaceuticals Ltd. ("XTL")


XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical needs. XTL is focused on late stage clinical development of drugs for the treatment of lupus, multiple myeloma and schizophrenia.

XTL is a public company traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Please see the risk factors associated with an investment in our ADSs or ordinary shares which are included in our Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission on April 2, 2014.

Investor Contacts:

Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 9 955 7080
Email: [email protected]
www.xtlbio.com


 

XTL Biopharmaceuticals, Ltd. and Subsidiaries

(in thousands, except share and per share amounts)


Consolidated Statements of Financial Position - Selected Data


As of

December 31,


December 31,


2014


2013





Cash, Cash Equivalents and bank deposits

$              2,159


$                  4,165

Working Capital

2,102


3,870

Total assets

5,644


8,015





Long term liabilities

$                    -


$                       11

Total shareholders' equity

4,660


6,265

Non-controlling interests

19


520










XTL Biopharmaceuticals, Ltd. and Subsidiaries





(USD in thousands, except share and per share amounts)

 





Consolidated Statements of Comprehensive Income

 






For the year ended


For the three months ended

December 31,


December 31,        


2014


2013


2014


2013

Research and Development expenses

(278)


(82)


(157)


(35)

General and administrative expenses

(1,744)


(1,329)


(519)


(316)

Other gains, net

-


1,059


-


3

Operating Loss

$              (2,022)


$                     (352)


$                  (676)


$                     (348)

Finance income

$                      41


$                        114


$                       17


$                            7

Finance expenses

(138)


(55)


(129)


(10)

Finance income (expenses), net

$                    (97)


$                         59


$                  (112)


$                         (3)

Losses from investment in associate

$                         -


$                     (845)


$                         -


$                            -

Total loss from continuing operations

$              (2,119)


$                  (1,138)


$                  (788)


$                     (351)









Total loss from discontinued operations

$                 (746)


$                  (2,575)


$                  (126)


$                  (1,133)









Total loss for the period

$              (2,865)


$                  (3,713)


$                  (914)


$                  (1,484)









Other comprehensive income (expenses):








Items that might be classified to profit or loss:








Foreign currency transaction adjustments

$                         -


$                        108


$                          -


$                             -

Reclassification of foreign currency transaction adjustments to Other gains, net

-


(221)


-


-

Total other comprehensive expenses

$                         -


$                     (113)


$                          -


$                             -









Total comprehensive loss for the period

$              (2,865)


$                 (3,826)


$                  (914)


$                  (1,484)









Total loss for the period attributable to:








Equity holders of the Company

$              (2,527)


$                  (2,476)


$                  (857)


$                     (971)

Non-controlling interests

(338)


(1,237)


(57)


(513)


$              (2,865)


$                  (3,713)


$                  (914)


$                  (1,484)

Total comprehensive loss for the period attributable to:








Equity holders of the Company

$              (2,527)


$                  (2,589)


$                  (857)


$                     (971)

Non-controlling interests

(338)


(1,237)


(57)


(513)


$              (2,865)


$                  (3,826)


$                  (914)


$                  (1,484)









Basic and diluted loss per share (in U.S. dollars):








From continuing operations

(0.009)


(0.005)


(0.003)


(0.001)

From discontinued operations

(0.002)


(0.006)


-


(0.003)

Total basic and diluted loss per share (in U.S. dollars)

$              (0.011)


$                 (0.011)


$               (0.003)


$                 (0.004)

Weighted average number of issued ordinary shares

231,224,512


223,605,181


232,812,446


226,477,137

SOURCE XTL Biopharmaceuticals Ltd.

Related Links

http://www.xtlbio.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.